References
- Manoli I, Venditti CP. Methylmalonic acidemia. GeneReviews at GeneTests: Medical Genetics Information Resource (database online): Copyright, University of Washington, Seattle, WA; 1997-2011, updated 2010.
- van der Meer SB, Poggi F, Spada M, Bonnefont JP, Ogier H, Hubert P, et al. Clinical outcome of longterm management of patients with vitamin B12-unresponsive methylmalonic acidemia. J Pediatr 1994;125 (6 Pt 1):903-8. https://doi.org/10.1016/S0022-3476(05)82005-0
- Cosson MA, Benoist JF, Touati G, Dechaux M, Royer N, Grandin L, et al. Long-term outcome in methylmalonic aciduria: a series of 30 French patients. Mol Genet Metab 2009;97(3):172-8. https://doi.org/10.1016/j.ymgme.2009.03.006
- Horster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, et al. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). Pediatr Res 2007;62: 225-30. https://doi.org/10.1203/PDR.0b013e3180a0325f
- Bianchi ML. Osteoporosis in children and adolescents. Bone 2007;41:486-95. https://doi.org/10.1016/j.bone.2007.07.008
- Lee JE, Lee HO, Paik KH, Lee SH, Jin DK. Therapeutic efficacy of alendronate for glucocorticoid induced metabolic bone disease in children with nephrotic syndrome. J Korean Soc Pediatr Nephrol 2004;8:33-42.
- Rauch F, Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long? Annals of Medicine 2005;37:295-302. https://doi.org/10.1080/07853890510007386
- Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Archives of Disease in Childhood 2002; 86:356-64. https://doi.org/10.1136/adc.86.5.356
- Zwickler T, Haege G. Metabolic decompensation in methylmalonic aciduria: which biochemical parameters are discriminative? J Inherit Metab Dis 2012;35:797-806. https://doi.org/10.1007/s10545-011-9426-1
- Walter JH, Michalski A, Wilson WM, Leonard JV, Barratt TM, Dillon MJ. Chronic renal failure in methylmalonic acidaemia. Eur J Pediatr 1989:148:344-8. https://doi.org/10.1007/BF00444131
- Zsengeller ZK1. Methylmalonic acidemia: a megamitochondrial disorder affecting the kidney. Pediatr Nephrol 2014 Nov;29.
- Rodd C, Goodyer P. Hypercalcemia of the newborn: etiology, evaluation, and management. Pediatr Nephrol 1999;13:542-7. https://doi.org/10.1007/s004670050654
- Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. Curr Opin Pediatr 2010;22:508-15. https://doi.org/10.1097/MOP.0b013e32833b7c23
- Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992;326:1196-203. https://doi.org/10.1056/NEJM199204303261806
- Rice AM, Rivkees SA. Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn. J Pediatr 1999;134:349-51. https://doi.org/10.1016/S0022-3476(99)70462-2
- Lee JE, Yoon JY, Lee YA, Lim JS, Shin CH, SW Yang. Pamidronate Therapy in Children and Adolescents with Secondary Osteoporosis. J Korean Soc Pediatr Endocrinol 2011;16:178-84. https://doi.org/10.6065/jkspe.2011.16.3.178
- Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94(2):400-9. doi: 10.1210/jc.2008-1531.
- Chilbule SK, Madhuri V. Complications of pamidronate therapy in paediatric osteoporosis. J Child Orthop 2012;6:37-43. https://doi.org/10.1007/s11832-012-0383-5
- DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006;21:132-140.